(Total Views: 443)
Posted On: 09/17/2019 11:09:25 AM
Post# of 152416
Yes, I thought that quote was encouraging, but after the annual meeting comments, I'm preparing for later in the year to get CMC portion of the BLA filed. Maybe NP has / is finally learning to under-promise and we will be pleasantly surprised if it comes sooner.
Another quote I thought important/encouraging: "across the various extension trials, there are now over 150 HIV treatment-resistant patients that have been exclusively on Leronlimab (PRO140) monotherapy for over one year."
And one not so much (I didn't think they would have a drug resistant label for mono): "The company also plans to initiate a 48-week Phase 3 registration study of Leronlimab (PRO140) as a monotherapy for drug resistant HIV patients"
Another quote I thought important/encouraging: "across the various extension trials, there are now over 150 HIV treatment-resistant patients that have been exclusively on Leronlimab (PRO140) monotherapy for over one year."
And one not so much (I didn't think they would have a drug resistant label for mono): "The company also plans to initiate a 48-week Phase 3 registration study of Leronlimab (PRO140) as a monotherapy for drug resistant HIV patients"
(2)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼
